These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32635430)

  • 1. Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570.
    Pellegrini P; Selvaraju K; Faustini E; Mofers A; Zhang X; Ternerot J; Schubert A; Linder S; D Arcy P
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute lymphoblastic leukemia cells are sensitive to disturbances in protein homeostasis induced by proteasome deubiquitinase inhibition.
    Mazurkiewicz M; Hillert EK; Wang X; Pellegrini P; Olofsson MH; Selvaraju K; D'Arcy P; Linder S
    Oncotarget; 2017 Mar; 8(13):21115-21127. PubMed ID: 28423502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VLX1570 induces apoptosis through the generation of ROS and induction of ER stress on leukemia cell lines.
    Kurozumi N; Tsujioka T; Ouchida M; Sakakibara K; Nakahara T; Suemori SI; Takeuchi M; Kitanaka A; Shibakura M; Tohyama K
    Cancer Sci; 2021 Aug; 112(8):3302-3313. PubMed ID: 34032336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
    Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
    Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System.
    Selvaraju K; Lotfi K; Gubat J; Miquel M; Nilsson A; Hill J; Jensen LD; Linder S; D'Arcy P
    Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
    Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
    Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia.
    Lust S; Vanhoecke B; VAN Gele M; Boelens J; VAN Melckebeke H; Kaileh M; Vanden Berghe W; Haegeman G; Philippé J; Bracke M; Offner F
    Anticancer Res; 2009 Oct; 29(10):3797-805. PubMed ID: 19846911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
    Paulus A; Akhtar S; Caulfield TR; Samuel K; Yousaf H; Bashir Y; Paulus SM; Tran D; Hudec R; Cogen D; Jiang J; Edenfield B; Novak A; Ansell SM; Witzig T; Martin P; Coleman M; Roy V; Ailawadhi S; Chitta K; Linder S; Chanan-Khan A
    Blood Cancer J; 2016 Nov; 6(11):e492. PubMed ID: 27813535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells.
    Rodvold JJ; Chiu KT; Hiramatsu N; Nussbacher JK; Galimberti V; Mahadevan NR; Willert K; Lin JH; Zanetti M
    Sci Signal; 2017 Jun; 10(482):. PubMed ID: 28588081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
    Obeng EA; Carlson LM; Gutman DM; Harrington WJ; Lee KP; Boise LH
    Blood; 2006 Jun; 107(12):4907-16. PubMed ID: 16507771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.
    Mofers A; Perego P; Selvaraju K; Gatti L; Gullbo J; Linder S; D'Arcy P
    PLoS One; 2019; 14(10):e0223807. PubMed ID: 31639138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
    Rowinsky EK; Paner A; Berdeja JG; Paba-Prada C; Venugopal P; Porkka K; Gullbo J; Linder S; Loskog A; Richardson PG; Landgren O
    Invest New Drugs; 2020 Oct; 38(5):1448-1453. PubMed ID: 32125598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
    Nawrocki ST; Carew JS; Dunner K; Boise LH; Chiao PJ; Huang P; Abbruzzese JL; McConkey DJ
    Cancer Res; 2005 Dec; 65(24):11510-9. PubMed ID: 16357160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
    Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib improves the development of acute lymphoblastic leukemia by activating endoplasmic reticulum stress-induced cell death.
    Li Z; Wu J; Sheng L
    Pharmazie; 2018 May; 73(5):294-299. PubMed ID: 29724297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of bortezomib-adapted I-45 mesothelioma cells.
    Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
    Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α, IRE1α, ATF6 and calmodulin kinase.
    Merlot AM; Shafie NH; Yu Y; Richardson V; Jansson PJ; Sahni S; Lane DJR; Kovacevic Z; Kalinowski DS; Richardson DR
    Biochem Pharmacol; 2016 Jun; 109():27-47. PubMed ID: 27059255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
    Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism.
    Modernelli A; Naponelli V; Giovanna Troglio M; Bonacini M; Ramazzina I; Bettuzzi S; Rizzi F
    Sci Rep; 2015 Oct; 5():15270. PubMed ID: 26471237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polychlorinated biphenyl quinone induces endoplasmic reticulum stress, unfolded protein response, and calcium release.
    Xu D; Su C; Song X; Shi Q; Fu J; Hu L; Xia X; Song E; Song Y
    Chem Res Toxicol; 2015 Jun; 28(6):1326-37. PubMed ID: 25950987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.